<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557451</url>
  </required_header>
  <id_info>
    <org_study_id>BRON PHRC I 2013</org_study_id>
    <nct_id>NCT02557451</nct_id>
  </id_info>
  <brief_title>Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications</brief_title>
  <acronym>STAR</acronym>
  <official_title>Subretinal Haematoma in AMD: Randomized Controlled Study of 2 Therapeutic Approaches in the Antiangiogenic Era</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      AMD is a disease of the central retina, a zone that enables fine detail activities (reading,
      detail…). This central zone of the retina can be affected by a haemorrhagic complication when
      small abnormal vessels suddenly start to bleed inside the retina. Several therapeutic
      approaches are currently available even though they have never been truly compared. The study
      will be proposed to patients who need to be treated for haemorrhage of the macula. A certain
      number of factors will be evaluated to compare the 2 principal approaches currently used in
      France: surgery followed by injections of an anti-angiogenic OR intravitreal injections of
      gas followed by injections of anti-angiogenics. This is a multicentre, randomized controlled
      trial to compare these 2 therapeutic approaches.

      These diametrically opposed approaches have very different consequences for patients and in
      terms of cost for society. The consequences for patients will be immediately measurable so as
      to determine the best therapeutic approach in terms of functional recovery and the impact of
      the disease on quality of life, while taking into account the risks inherent to these 2
      treatments. The impact on quality of life of these 2 approaches as well as their consequences
      - an important factor in this disease, which is a cause of sensory handicap - will provide
      the ophthalmological community with essential information making it possible to validate one
      or the other of these methods for the management of these haematomas.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2016</start_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity measured on the ETDRS scale</measure>
    <time_frame>Change from inclusion at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity measured on the ETDRS scale</measure>
    <time_frame>At 1 month and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of the scotoma presented by the patient according to the Amsler grid</measure>
    <time_frame>At 1 month, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the VFQ-25 scale</measure>
    <time_frame>At 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections of an antiangiogenic at the end of the 6 months of treatment</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with macular bleeding</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of hypoautofluorescence using the autofluorescence technique</measure>
    <time_frame>At 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Subretinal Haematoma Linked to AMD</condition>
  <arm_group>
    <arm_group_label>surgery + antiangiogenic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgery (vitrectomy - air - TPA) with injections of an antiangiogenic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravitreal injection of gas/TPA + antiangiogenic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravitreal injection of gas - TPA with injections of an antiangiogenic</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <arm_group_label>surgery + antiangiogenic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravitreal injections of gas</intervention_name>
    <arm_group_label>intravitreal injection of gas/TPA + antiangiogenic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>injections of an antiangiogenic</intervention_name>
    <arm_group_label>surgery + antiangiogenic</arm_group_label>
    <arm_group_label>intravitreal injection of gas/TPA + antiangiogenic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients presenting subretinal haematoma linked to AMD

          -  Occurring at least14 days before the start of therapy

          -  With the presence of a component overlying the pigmentary epithelium (PE) on the OCT

          -  And a diameter greater than two pupillary diameters on the retinal photographs

        Patients who have provided oral consent

        Patients with National Health Insurance cover

        Patients available for monthly follow-up

        Patient having an effective contraception for the women old enough to procreate during the
        treatment and during 6 months which follow his stop.

        Exclusion Criteria:

          -  Subretinal haematoma linked to a cause other than AMD (myopia, angioid streaks…)

          -  History of subretinal haematoma on the same side

          -  Cloudy humour making it impossible to photograph the fundus of the eye or carry out
             angiography

          -  Component of the haematoma exclusively underlying the pigmentry epithelium

          -  Haemorrhage without lifting of the retina

          -  Patients presenting an INR greater than 4, thus contra-indicating surgery

          -  Patients requiring cataract surgery in the first 3 months of the study

          -  Patients presenting a contra-indication relative to injection of the antiangiogenic
             (History of AVC bleeding or unknown origin in the last 6 months or MI in the 3
             preceding months)

          -  Pregnant or breast-feeding woman (the patients do not have to breast-feed during at
             least 6 months after the administration of the last dose of the antiangiogénique)

          -  Contraindication in the use of ranibizumab: hypersensitivity in the active ingredient
             or in one of the excipients, eye infection or périoculaire active or suspected,
             inflammation intraoculaire active severe, treatments anti-VEGF systematic or eye
             concomitant,

          -  Contraindication in the use of bevacizumab: hypersensitivity in the active substance
             or in one of the excipients, the hypersensitivity in the products of the ovarian cells
             of Chinese hamster (CHO) or in other antibodies human or humanized recombinants, heavy
             surgical operation dating less than 28 days, not totally healed surgical wound,
             history of lung bleeding or hémoptysie

          -  Contraindication in the use of alteplase: hypersensitivity in the active substance, in
             the gentamicine (a residue of the present manufacturing process in the state of
             tracks), or in one of the excipients. As all the thrombolytic agents, contraindication
             in every case associated to a high hemorrhagic risk (current significant hemorrhagic
             disorder or during the last six months, hemorrhagic known diathesis, concomitant
             treatment by oral anticoagulants with effective dose, severe or potentially dangerous,
             obvious or recent bleeding, histories or suspicion of intra-cranial bleeding,
             suspicion of sub-arachnoid bleeding or history of sub-arachnoid bleeding bound to an
             aneurysm, histories of severe lesion of the central nervous system (for example
             néoplasie, aneurysm, surgical operation intracerebral or intrathecal), recent
             traumatic external cardiac massage (less than 10 days), delivery, recent draining of a
             vessel not accessible to the compression (for example draining of the subclavian or
             jugular vein),severe uncontrolled high blood pressure, bacterial endocarditis,
             pericarditis, acute pancreatitis, gastrointestinal ulcers documented during the last 3
             months, esophageal varices, arterial aneurysm, arterial or venous deformations,
             neoplasia increasing the hemorrhagic risk, severe hepatic disease, including hepatic
             insufficiency, cirrhosis, portal hypertension (esophageal varicose veins) and
             evolutionary hepatitis, surgical operation or important traumas during the last 3
             months.

          -  Contraindication in the use of acetazolamide: hypersensitivity in the acetazolamide or
             in one of excipients, severe hepatic, renal or suprarenal inadequacies, intolerance in
             sulphonamide, histories of renal colic, allergy in the wheat (other than the coeliac
             disease).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Alain BRON</last_name>
    <phone>3 80 29 51 73</phone>
    <phone_ext>+33</phone_ext>
    <email>alain.bron@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de BESANCON</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maher SALEH</last_name>
      <phone>381667416</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Noëlle DELYFER</last_name>
      <phone>557821216</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de COLMAR</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MEYER</last_name>
      <phone>626845294</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI de CRETEIL</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès GLACET-BERNARD</last_name>
      <phone>145175221</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain BRON</last_name>
      <phone>3 80 29 51 73</phone>
      <phone_ext>+33</phone_ext>
      <email>alain.bron@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe CHIQUET</last_name>
      <phone>476768457</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent KODJIKIAN</last_name>
      <phone>472071718</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR de METZ-THIONVILLE</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc PERONE</last_name>
      <phone>387553428</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de MULHOUSE</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LENOBLE</last_name>
      <phone>389646205</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de NEVERS</name>
      <address>
        <city>Nevers</city>
        <zip>58000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akram GHRER</last_name>
      <phone>668150174</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramin TADAYONI</last_name>
      <phone>149956488</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick LE MER</last_name>
      <phone>148036671</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de REIMS</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl ARNDT</last_name>
      <phone>326787090</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Mathilde</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël UZZAN</last_name>
      <phone>609023911</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHC de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David GAUCHER</last_name>
      <phone>369550437</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent SOLER</last_name>
      <phone>561772233</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de NANCY</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul BERROD</last_name>
      <phone>383155101</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

